RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs Business Wire NOKOMIS, Fla. -- March 6, 2013 Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new medical technologies and innovations, today reports its anticipation of partnering with a cutting-edge genome-mapping facility in Houston in the next few weeks. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017. The cutting-edge science of pharmacogenomics is a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. RBCC sees it as the future of medicine. “This is the next evolution in personalized medicine,” said RBCC CEO Patrick Brown. “Important differences in drug metabolism and response from person to person are often rooted in our genes. By studying a patient’s genotype, doctors can eliminate the trial-and-error approach to tailoring a safer, more efficient and more effective drug treatment plan.” RBCC is turning its full attention to the exploration of new promising opportunities now that the company will no longer be partnering with Amarantus Biosciences, which has elected to pursue other opportunites. RBCC wishes Amarantus much success moving forward, and remains open to future partnering opportunities with the company. In addition to its pharmacogenomics talks, RBCC is also currently working on a joint venture agreement with a privately held drug delivery company that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. For more information on Rainbow BioSciences’ current projects, please visitwww.rainbowbiosciences.com/investors.html. Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN). About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visitwww.RainbowBioSciences.com/investors.html. Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. Contact: Rainbow Coral Corp. Patrick Brown, 813-367-9511 President and CEO firstname.lastname@example.org
RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs
Press spacebar to pause and continue. Press esc to stop.